Brief: Jazz Pharmaceuticals To Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
10/08/2026 14:47
BRIEF-Jazz Pharmaceuticals To Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Aug 10 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O:
JAZZ PHARMACEUTICALS TO ACQUIRE ACTIO BIOSCIENCES, EXPANDING RARE EPILEPSY PORTFOLIO
JAZZ PHARMACEUTICALS - TO BUY ACTIO BIOSCIENCES FOR $820 MILLION UPFRONT, UP TO $500 MILLION CONTINGENT
JAZZ PHARMACEUTICALS - ACTIO BIOSCIENCES TO SPIN OUT NEW PRIVATE ENTITY; JAZZ TO RECEIVE MINORITY STAKE
JAZZ PHARMACEUTICALS - TO FUND DEAL WITH CASH ON HAND AND EXISTING FINANCING FACILITIES
JAZZ PHARMACEUTICALS - DEAL EXPECTED TO CLOSE BY Q4 2026, SUBJECT TO CONDITIONS
Source text: ID:nPn7pwhgZa
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032